Gilead forecasts FY26 Yeztugo revenue at about $1 billion - GILD News | RalliesGilead forecasts FY26 Yeztugo revenue at about $1 billion
G
GILD• FY26 revenue guidance and product outlook
- Gilead guided for FY26 HIV revenue growth of 9%-10% year over year, led by Biktarvy, Yeztugo, Descovy.
- FY26 Yeztugo revenue expected near USD 1 billion; Q2 sales reached USD 232 million, up 40% quarter over quarter.
- Cell therapy revenue forecast to fall by a mid-teens percentage in FY26; Q2 sales were USD 417 million, down 14% year over year.
- Veklury revenue outlook set at about USD 300 million for FY26; Q2 sales were USD 23 million, down 81% year over year.
•
